Orbit Genomics
Orbit Genomics is redefining precision medicine with its AI-powered OrbiSeq™ technology, which analyzes short tandem repeats (STRs) in DNA to reveal inherited and acquired disease risks. Unlike traditional tests focusing on static genetic mutations, OrbiSeq offers a personalized view of health trajectories. Built on NIH-funded research, the platform identifies genomic signals missed by standard sequencing, with applications in early disease diagnosis, companion diagnostics, therapeutic target discovery, and aging-related risk. The company is developing products for cancer, cardiovascular, neurological, and inflammatory diseases, aiming to unlock a crucial part of the genomics puzzle. Their focus includes improving early cancer diagnosis, with OrbiSeq™-L targeting indeterminate pulmonary nodules in lung cancer patients as a non-invasive alternative to biopsies, and a future indication as a pre-screening test for LDCT.
Orbit Genomics
Orbit Genomics is redefining precision medicine with its AI-powered OrbiSeq™ technology, which analyzes short tandem repeats (STRs) in DNA to reveal inherited and acquired disease risks. Unlike traditional tests focusing on static genetic mutations, OrbiSeq offers a personalized view of health trajectories. Built on NIH-funded research, the platform identifies genomic signals missed by standard sequencing, with applications in early disease diagnosis, companion diagnostics, therapeutic target discovery, and aging-related risk. The company is developing products for cancer, cardiovascular, neurological, and inflammatory diseases, aiming to unlock a crucial part of the genomics puzzle. Their focus includes improving early cancer diagnosis, with OrbiSeq™-L targeting indeterminate pulmonary nodules in lung cancer patients as a non-invasive alternative to biopsies, and a future indication as a pre-screening test for LDCT.